Triple incretin receptor agonist (investigational)
An investigational synthetic peptide studied as a triple agonist of the GIP, GLP-1, and glucagon receptors in metabolic research.
Retatrutide is an investigational synthetic peptide that has been described in the scientific literature as an agonist acting at three receptors involved in metabolic signaling: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor.
It is studied in the broader research field of incretin biology, where naturally occurring gut hormones such as GLP-1 and GIP participate in glucose-dependent signaling. Retatrutide is a research compound and is not an approved product.
No. Retatrutide is described in the scientific literature as an investigational compound. NorthPeak presents it as an informational research entry only.
Published research describes it as an agonist at the GIP, GLP-1, and glucagon receptors — three receptors involved in metabolic signaling.
Research disclaimer. All information on NorthPeak Peptides is provided for educational and informational purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. Materials referenced are described for research context and are not offered for human consumption. Always consult a qualified, licensed healthcare professional regarding your health.
Mitochondrial-derived peptide
A mitochondrial-derived peptide studied in metabolic-regulation and cellular-energy research.
View Research ProfileSynthetic peptide related to Thymosin β-4
A synthetic peptide associated with the actin-binding region of Thymosin β-4, studied in cell-migration and tissue-repair research models.
View Research ProfileBody Protection Compound-157 (pentadecapeptide)
A synthetic pentadecapeptide derived from a sequence identified in gastric juice, studied in cytoprotection and tissue-repair research models.
View Research Profile